- A pancreatic tissue sample is obtained for research purposes from a recently deceased individual with a long-standing history of diabetes. Microscopic examination reveals significant deposition of amyloid polypeptide within the islets of Langerhans and a moderate reduction in beta-cell mass, but no significant inflammatory infiltrate. These findings are most characteristic of which underlying pathophysiology?
Answer: Chronic insulin resistance leading to beta-cell exhaustion and apoptosis, with co-secretion and aggregation of islet amyloid polypeptide.
The histological hallmark described—islet amyloid deposition—is characteristic of Type 2 diabetes. Islet amyloid polypeptide (IAPP, or amylin) is co-secreted with insulin. In the setting of insulin resistance and chronic hyperinsulinemia, IAPP is overproduced, misfolds, and aggregates into toxic fibrils that deposit in the islets, contributing to beta-cell dysfunction and apoptosis. The absence of an inflammatory infiltrate (insulitis) argues against Type 1 diabetes.
* B is incorrect because T-lymphocyte mediated assault (insulitis) is the characteristic histological finding in Type 1 diabetes, which was explicitly noted as absent.
* C is incorrect because while viral infections are a proposed trigger for T1DM, they do not typically result in amyloid deposition.
* D is incorrect because while defects in glucose sensing can cause diabetes (e.g., some forms of MODY), they are not primarily characterized by amyloid deposition.
- The concept of 'glucotoxicity' describes how chronic hyperglycemia can itself impair insulin secretion and action. How does this phenomenon contribute differently to the progression of Type 1 versus Type 2 diabetes?
Answer: In Type 2, it is a core mechanism that perpetuates a cycle of worsening beta-cell dysfunction, whereas in Type 1, it contributes to the initial metabolic decompensation but its reversal can temporarily restore some beta-cell function.
Glucotoxicity plays a role in both types, but its context is different. In Type 2 diabetes, it's a crucial part of a vicious cycle: insulin resistance causes hyperglycemia, which is toxic to the beta-cells, impairing their ability to secrete insulin, which in turn worsens hyperglycemia. This accelerates the progression of the disease. In Type 1 diabetes, the profound hyperglycemia at diagnosis also impairs the function of the few remaining beta-cells. When insulin therapy is started and glucose levels fall, this glucotoxicity is relieved, allowing those cells to function better temporarily, which is the basis for the 'honeymoon period'.
* B is incorrect because glucotoxicity impairs both insulin secretion and insulin sensitivity in both conditions.
* C is incorrect because glucotoxicity is not the trigger for the autoimmune process in T1DM, and it is a major driver of progression in T2DM, not a minimal consequence.
* D is incorrect because the effects of glucotoxicity on beta-cell function are at least partially reversible in both types, as evidenced by the T1DM honeymoon period and the improvement in beta-cell function in T2DM with better glycemic control.
- In an untreated individual with Type 1 diabetes, the absolute lack of insulin profoundly alters lipid metabolism. Which of the following is a direct pathophysiological consequence of this state?
Answer: Unrestrained lipolysis in adipose tissue, leading to a massive efflux of free fatty acids into the circulation.
Insulin is a potent inhibitor of hormone-sensitive lipase (HSL), the key enzyme for breaking down stored triglycerides in adipocytes. In the absolute insulin deficiency of Type 1 diabetes, HSL activity is completely unrestrained. This leads to massive lipolysis, releasing large quantities of free fatty acids (FFAs) and glycerol into the bloodstream. These FFAs are then taken up by the liver and serve as the substrate for the rampant ketogenesis seen in DKA.
* B is incorrect because hepatic steatosis is more characteristic of the hyperinsulinemic, insulin-resistant state of Type 2 diabetes, where excess energy is shunted towards lipid synthesis in the liver.
* C is incorrect because insulin activates LPL to promote fat storage. A lack of insulin would decrease LPL activity, impairing the clearance of circulating lipids.
* D is incorrect because ketogenesis occurs in the liver mitochondria, and the substrate is fatty acids, not glucose directly.
- A 38-year-old obese woman is diagnosed with gestational diabetes mellitus (GDM). Post-partum, her glucose tolerance test is normal. However, she is counseled that she is at very high risk for developing Type 2 diabetes. The underlying pathophysiological state that connects her GDM to her future risk is most likely:
Answer: a pre-existing subclinical insulin resistance and limited beta-cell reserve that was overwhelmed by the hormonal changes of pregnancy.
When you encounter questions about gestational diabetes and future Type 2 diabetes risk, think about the underlying metabolic state that predisposes to both conditions rather than pregnancy-specific pathology.
Gestational diabetes occurs when pregnancy hormones (like human placental lactogen and cortisol) increase insulin resistance, but the woman's pancreatic beta cells cannot compensate adequately. The key insight is that healthy women with normal beta-cell function and insulin sensitivity can handle this metabolic stress without developing hyperglycemia. Women who develop GDM likely already had subclinical insulin resistance and marginal beta-cell reserve before pregnancy—the hormonal changes of pregnancy simply unmasked this underlying vulnerability.
After delivery, when pregnancy hormones disappear, glucose tolerance normalizes because the metabolic stress is removed. However, the fundamental problem—insulin resistance and limited beta-cell capacity—remains. Over time, this predisposes to Type 2 diabetes as insulin resistance progresses and beta-cell function gradually declines.
Option A incorrectly suggests an autoimmune mechanism, which characterizes Type 1 diabetes, not the insulin resistance syndrome underlying GDM and Type 2 diabetes. Option B wrongly implies complete beta-cell exhaustion during pregnancy—if this were true, the woman wouldn't have normal glucose tolerance post-partum. Option C describes anti-insulin receptor antibodies, an extremely rare cause of diabetes that doesn't explain the typical GDM-to-Type 2 diabetes progression.
Remember: GDM is essentially a "stress test" that reveals pre-existing metabolic dysfunction. Women who "fail" this test have demonstrated their susceptibility to insulin resistance-related diabetes.
- An endocrinologist is counseling two families about their genetic risk for diabetes. Family A has a child with Type 1 diabetes. Family B has a parent with Type 2 diabetes. Which statement most accurately contrasts the genetic predisposition in these two scenarios?
Answer: The development of Type 1 diabetes is strongly linked to specific HLA class II alleles, while Type 2 diabetes involves multiple susceptibility genes and has a higher concordance rate in identical twins.
The genetic bases for T1DM and T2DM are distinct. T1DM is an autoimmune disease strongly associated with specific human leukocyte antigen (HLA) haplotypes (e.g., HLA-DR3, -DR4) on chromosome 6. T2DM has a stronger overall genetic component (higher monozygotic twin concordance rate, ~70-90%) but is polygenic, meaning many genes contribute small effects to the overall risk.
* A is incorrect because the concordance rate for monozygotic twins is much higher for Type 2 diabetes (~70-90%) than for Type 1 diabetes (~40-50%).
* C is incorrect because neither T1DM nor common T2DM are single-gene (monogenic) disorders. Monogenic forms of diabetes like MODY exist but are rare.
* D is incorrect because while rare forms of mitochondrial diabetes exist, the vast majority of T2DM cases follow a polygenic, autosomal inheritance pattern, not exclusively maternal.
- In the pathophysiology of Type 2 diabetes, insulin resistance in skeletal muscle is a key defect. This resistance is primarily caused by an intracellular impairment of:
Answer: the post-receptor signaling cascade that links insulin receptor activation to the translocation of GLUT4-containing vesicles.
The central defect in muscle insulin resistance is not with the insulin receptor itself or the amount of GLUT4 protein, but with the signaling pathway that occurs after insulin binds to its receptor. This complex pathway involves phosphorylation of proteins like Insulin Receptor Substrate (IRS) and activation of kinases like PI3K and Akt. In T2DM, this pathway is impaired, often due to the accumulation of intracellular lipid metabolites (e.g., diacylglycerol, ceramides) that interfere with these signaling proteins. As a result, the signal to move GLUT4 transporters to the cell membrane is weakened, leading to reduced glucose uptake.
* A is incorrect because while receptor numbers can be downregulated, the major defect is post-receptor.
* C is incorrect because ATP production is not the rate-limiting step.
* D is incorrect because the total amount of GLUT4 protein in the cell is generally normal; the problem is getting it to the cell surface where it can transport glucose.
- A patient with long-standing Type 2 diabetes has fasting hyperglycemia primarily due to elevated hepatic glucose output. His labs show high fasting insulin and high fasting glucagon. The persistence of high glucagon levels despite hyperinsulinemia is best explained by:
Answer: alpha-cell resistance to the normal paracrine inhibitory effects of insulin, leading to a failure to suppress glucagon secretion.
A key feature of the dysregulated islet in Type 2 diabetes is the failure of alpha-cells to suppress glucagon secretion in response to glucose or insulin. Normally, insulin released from beta-cells acts locally (paracrine effect) to inhibit glucagon release from alpha-cells. In T2DM, the alpha-cells become resistant to this inhibitory effect of insulin. Therefore, even when insulin levels are high, glucagon secretion continues unabated, contributing significantly to hepatic glucose production and hyperglycemia.
* A is incorrect because while somatostatin regulation may be altered, a complete absence is not the primary mechanism, and the specific resistance of alpha-cells to insulin is a more direct explanation.
* B is incorrect because this central nervous system mechanism is not the established primary cause of alpha-cell dysregulation.
* D is incorrect because while renal clearance affects hormone levels, the fundamental problem is inappropriate secretion from the pancreas, not differential clearance.
- A 14-year-old is diagnosed with Type 1 diabetes and started on insulin therapy. After several weeks, her insulin requirements decrease significantly, and she experiences several episodes of hypoglycemia. This 'honeymoon period' is best explained by which pathophysiological phenomenon?
Answer: A temporary restoration of endogenous insulin secretion from remaining beta-cells that have recovered from the initial effects of severe hyperglycemia.
The honeymoon period in Type 1 diabetes occurs after the initiation of insulin therapy. The exogenous insulin corrects the severe hyperglycemia and metabolic derangement (glucotoxicity and ketosis). This improved metabolic environment allows the remaining, non-destroyed beta-cells to recover some function and resume secreting a small amount of endogenous insulin. This temporary recovery reduces the need for exogenous insulin. The period ends as the ongoing autoimmune process eventually destroys these remaining cells.
* A is incorrect as insulin-sensitizing antibodies are not a known mechanism.
* B is incorrect because beta-cells do not regenerate, and the autoimmune process is still active.
* D is incorrect because while insulin sensitivity does improve with better glycemic control, the primary driver of the honeymoon phenomenon is the return of some endogenous insulin secretion.
- A 45-year-old male with a BMI of 32 kg/m² presents with polyuria and polydipsia. Lab tests show a fasting plasma glucose of 180 mg/dL and a C-peptide level that is at the upper limit of the normal range. Which statement best explains the pathophysiological basis for these findings?
Answer: Peripheral tissues exhibit decreased responsiveness to insulin, requiring the pancreas to maintain a state of hyperinsulinemia to achieve glycemic control.
The patient's presentation (middle-aged, obese) and lab findings (hyperglycemia with high-normal C-peptide) are characteristic of early Type 2 diabetes. The high C-peptide level indicates that the pancreas is producing a significant amount of insulin. The fact that hyperglycemia persists despite this indicates peripheral insulin resistance. The pancreas is compensating by secreting more insulin (hyperinsulinemia) to try to overcome this resistance.
* B is incorrect because autoimmune destruction (Type 1 diabetes) would result in very low or undetectable C-peptide levels, indicating an absolute lack of insulin production.
* C is incorrect because the incretin effect is known to be blunted or diminished in Type 2 diabetes, not potentiated.
* D is incorrect because in Type 2 diabetes, glucagon secretion is typically inappropriately high, not suppressed, contributing to hyperglycemia.
- An 8-year-old boy presents with a one-week history of nocturia, weight loss, and lethargy, culminating in vomiting and rapid breathing. A 58-year-old obese man is found to have a fasting glucose of 150 mg/dL on routine screening, reporting only mild fatigue. The stark contrast in the acuity of their presentations is best explained by:
Answer: the rapid and near-total loss of insulin production in the boy, versus the slow, progressive decline in insulin sensitivity and secretion in the man.
When you encounter contrasting presentations of diabetes, think about the fundamental differences between Type 1 and Type 2 diabetes pathophysiology. The key is understanding how rapidly insulin deficiency develops in each condition.
The 8-year-old's acute presentation with nocturia, weight loss, vomiting, and rapid breathing (likely Kussmaul respirations) suggests diabetic ketoacidosis (DKA), characteristic of Type 1 diabetes. This occurs because autoimmune destruction of pancreatic beta cells leads to rapid, near-complete insulin deficiency. Without insulin, cells cannot utilize glucose, triggering lipolysis and ketone production. The adult's mild symptoms with elevated fasting glucose suggest Type 2 diabetes, where insulin resistance develops gradually over years, with progressive beta cell dysfunction but retained partial insulin production.
Answer D correctly identifies this pathophysiological difference: rapid, near-total insulin loss in Type 1 versus slow, progressive insulin resistance and secretion decline in Type 2.
Answer A incorrectly focuses on immune responses to hyperglycemia rather than the underlying insulin deficiency mechanisms. Answer B misunderstands glucose metabolism—body fat doesn't serve as a glucose storage reservoir; glycogen in liver and muscle does, but this doesn't explain the presentation differences. Answer C incorrectly suggests children have lower renal glucose thresholds, but the threshold is actually similar across age groups, and this wouldn't explain the metabolic acidosis seen in the boy.
Remember: acute, severe diabetes symptoms in children usually indicate Type 1 with rapid beta cell destruction, while gradual onset in adults typically reflects Type 2's progressive insulin resistance.
- A patient with known Type 1 diabetes presents with diabetic ketoacidosis (DKA). A patient with known Type 2 diabetes presents with hyperosmolar hyperglycemic state (HHS). What key pathophysiological difference explains why significant ketosis is a hallmark of DKA but is largely absent in HHS?
Answer: The absolute insulin deficiency in Type 1 diabetes leads to unopposed activation of hormone-sensitive lipase, whereas the residual insulin in Type 2 diabetes is sufficient to suppress ketogenesis.
Ketogenesis is driven by the breakdown of fats (lipolysis) in adipose tissue, releasing free fatty acids (FFAs) that are transported to the liver and converted into ketone bodies. The key regulator of this process is insulin, which strongly inhibits hormone-sensitive lipase, the enzyme that initiates lipolysis. In T1DM, the absolute lack of insulin leads to unrestrained lipolysis and massive FFA flux to the liver, fueling rampant ketogenesis. In T2DM, even during HHS, there is usually enough residual endogenous insulin to suppress lipolysis and ketogenesis, even though it is not enough to control hyperglycemia.
* A is incorrect because hyperosmolarity does not directly inhibit ketogenic enzymes; the lack of a ketogenic substrate (FFAs) is the issue.
* B is incorrect because the concept is simpler: it's not about differential sensitivity but the mere presence of some insulin, which is a potent anti-ketogenic signal.
* D is incorrect as this is not a known pathophysiological mechanism in T2DM.
- In a healthy individual, insulin suppresses hepatic glucose production (HGP). How is this regulatory mechanism altered differently in Type 1 versus Type 2 diabetes, both contributing to fasting hyperglycemia?
Answer: In Type 1, the absence of an insulin signal leads to unrestrained HGP; in Type 2, hepatic insulin resistance blunts the suppressive effect of circulating insulin.
Both T1DM and T2DM feature excessive hepatic glucose production (HGP), but for different reasons. In T1DM, there is an absolute lack of insulin. Since insulin is the primary signal to turn off HGP, its absence means the liver produces glucose unchecked, driven by high glucagon levels. In T2DM, insulin is present (and may even be high), but the liver is resistant to its effects. Therefore, the insulin signal to suppress HGP is ineffective, leading to continued glucose production despite hyperglycemia and hyperinsulinemia.
* A is incorrect because HGP is excessive and peripheral uptake is impaired in both conditions.
* B is incorrect because the liver remains sensitive to the stimulatory effects of glucagon in both types; the problem lies with the inhibitory insulin signal.
* D is incorrect because while counter-regulatory hormones like cortisol and glucagon drive HGP, the primary defect in both cases is the failure of insulin to suppress this production.
- The incretin effect describes the phenomenon where an oral glucose load elicits a much greater insulin response than an isoglycemic intravenous glucose infusion. How does the pathophysiology of Type 2 diabetes alter this physiological effect?
Answer: The effect is significantly diminished due to a combination of reduced GLP-1 secretion and beta-cell resistance to incretin hormones.
A key component of the pathophysiology of Type 2 diabetes is a blunted incretin effect. This means that after a meal, the gut releases less glucagon-like peptide-1 (GLP-1), and the pancreatic beta-cells are also less responsive to the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) that are released. This impairment contributes significantly to postprandial hyperglycemia.
* A is incorrect because the effect is diminished, not exaggerated. Reactive hypoglycemia is not a characteristic feature of the incretin defect in T2DM.
* C is incorrect because both the timing and the magnitude of the insulin response due to the incretin effect are impaired.
* D is incorrect because the impaired incretin effect is a well-established and important contributor to the pathophysiology of T2DM, alongside peripheral insulin resistance and beta-cell dysfunction.
- A 50-year-old sedentary patient with a new diagnosis of Type 2 diabetes is advised to start a regular exercise program. After 3 months, his fasting glucose and HbA1c levels have significantly improved without any change in medication. The primary mechanism responsible for this improvement is an exercise-induced increase in:
Answer: insulin-independent translocation of GLUT4 transporters to the plasma membrane in skeletal muscle.
Skeletal muscle is a major site of glucose disposal. Glucose enters muscle cells via GLUT4 transporters. In a resting state, this process is insulin-dependent. However, muscle contraction during exercise triggers a separate, insulin-independent signaling pathway that also results in the translocation of GLUT4 transporters to the cell surface. This allows for increased glucose uptake from the blood, thereby lowering blood glucose levels, a key benefit for individuals with insulin resistance.
* B is incorrect because exercise does not regenerate or increase the number of pancreatic beta-cells.
* C is incorrect because exercise improves hepatic insulin sensitivity, which leads to decreased hepatic glucose production. Increased glucagon sensitivity would worsen hyperglycemia.
* D is incorrect because this describes the mechanism of SGLT2 inhibitor medications, not the physiological effect of exercise.
- Amylin (islet amyloid polypeptide) is a hormone co-secreted with insulin from pancreatic beta-cells. Which statement correctly contrasts the role and fate of amylin in the pathophysiology of Type 1 versus Type 2 diabetes?
Answer: In Type 1, there is a co-deficiency of amylin with insulin, whereas in Type 2, amylin can aggregate into toxic amyloid fibrils that damage beta-cells.
When analyzing amylin's role in diabetes pathophysiology, focus on the fundamental difference between Type 1's autoimmune beta-cell destruction versus Type 2's progressive dysfunction with toxic protein accumulation.
In Type 1 diabetes, the autoimmune destruction of pancreatic beta-cells eliminates the source of both insulin and amylin production. Since these hormones are co-secreted from the same cells, patients develop a co-deficiency of both hormones from the onset. This creates the need for insulin replacement therapy and explains why Type 1 patients may benefit from amylin analogs like pramlintide.
Type 2 diabetes follows a different pathological pathway. Initially, beta-cells hypersecrete both insulin and amylin in response to insulin resistance. However, amylin has a tendency to misfold and aggregate into amyloid fibrils, particularly under conditions of chronic oversecretion. These toxic protein deposits accumulate in pancreatic islets, directly damaging beta-cells and contributing to their progressive dysfunction—a key feature distinguishing Type 2 from Type 1 pathophysiology.
Answer A incorrectly reverses the amylin patterns—Type 1 has absent secretion, not overproduction. Answer B mischaracterizes amylin's mechanisms; it doesn't primarily promote glucagon secretion or directly cause insulin resistance. Answer C wrongly suggests both types have amylin deficiency and incorrectly attributes Type 2's amylin issues to gene mutations rather than protein aggregation.
Remember this pattern: Type 1 = deficiency diseases (loss of hormone production), while Type 2 = dysfunction diseases (often involving toxic protein accumulation and progressive organ damage).
- A 22-year-old college student with a normal BMI presents with a 2-week history of polyuria, polydipsia, and a 10-lb weight loss. His random plasma glucose is 450 mg/dL. The presence of which of the following laboratory markers would most specifically support a diagnosis of Type 1 diabetes over Type 2 diabetes?
Answer: Antibodies against glutamic acid decarboxylase (GAD65).
Type 1 diabetes is an autoimmune disease. The most specific markers for this autoimmune process are the presence of autoantibodies directed against pancreatic islet antigens. GAD65 antibodies are one of the most common types. Their presence directly points to an autoimmune etiology.
* A is incorrect because an elevated HbA1c indicates hyperglycemia over the preceding 2-3 months and is diagnostic for diabetes in general, but does not differentiate between types.
* B is incorrect because while low C-peptide is highly suggestive of T1DM, it can also be seen in very late-stage, insulin-dependent T2DM where beta-cells have failed. Therefore, it is less specific for the underlying process than autoantibodies.
* D is incorrect because while ketonuria is much more common in T1DM, it can also occur in T2DM during periods of severe metabolic stress (e.g., infection), making it less specific than the presence of autoantibodies.
- A 42-year-old male with a BMI of 26 kg/m² is diagnosed with diabetes. He is initially managed with oral agents for suspected Type 2 diabetes but shows poor glycemic control and requires insulin within a year. C-peptide levels are found to be low, and GAD65 antibodies are positive. This clinical picture is most consistent with which pathophysiological process?
Answer: A slowly progressive autoimmune destruction of pancreatic beta-cells, representing a subtype of Type 1 diabetes.
This patient's presentation is classic for Latent Autoimmune Diabetes in Adults (LADA). LADA is a form of autoimmune diabetes (Type 1) that occurs in adults and has a slower rate of beta-cell destruction than classic childhood-onset T1DM. Key features are adult onset, positive autoantibodies (like GAD65), and progression to insulin dependence that is often faster than in T2DM. It is frequently misdiagnosed initially as T2DM.
* A is incorrect because MODY is a monogenic, non-autoimmune form of diabetes, so autoantibodies would be negative.
* B is incorrect because while rapid failure can occur in T2DM, the presence of GAD65 antibodies points specifically to an autoimmune etiology.
* D is incorrect because the patient did not have a pre-existing diagnosis of Type 1 diabetes from a younger age.
- A patient with Type 1 diabetes and a patient with Type 2 diabetes both present with fasting hyperglycemia. While insulin dysregulation is central to both, what is the distinct role of glucagon in the pathophysiology of Type 1 diabetes compared to Type 2?
Answer: The absence of intra-islet insulin leads to a loss of paracrine inhibition of alpha-cells, resulting in unchecked glucagon secretion and rampant ketogenesis.
In the pancreatic islet, insulin secreted from beta-cells normally acts in a paracrine fashion to suppress glucagon secretion from adjacent alpha-cells. In Type 1 diabetes, the destruction of beta-cells removes this inhibitory signal. This leads to unopposed and inappropriately high glucagon secretion, which drives excessive hepatic glucose production (gluconeogenesis, glycogenolysis) and ketone body formation (ketogenesis), especially during DKA.
* A is incorrect because in T1DM, glucagon is not suppressed by hyperglycemia due to the lack of the insulin signal. This lack of suppression is a key pathological feature.
* C is incorrect because the liver remains highly sensitive to glucagon's effects in T1DM; in fact, this sensitivity contributes to the severe hyperglycemia.
* D is incorrect because glucagon stimulates both glycogenolysis and gluconeogenesis in both conditions. The key difference is the degree of opposition from insulin.
- Beyond its role in energy storage, adipose tissue is an active endocrine organ. The pathophysiology of Type 2 diabetes is intricately linked to visceral adiposity, primarily because visceral fat:
Answer: releases inflammatory cytokines and free fatty acids that promote insulin resistance in the liver and skeletal muscle.
Visceral adipose tissue, the fat surrounding internal organs, is more metabolically active and pathogenic than subcutaneous fat. It undergoes lipolysis more readily, releasing free fatty acids (FFAs) directly into the portal circulation, which leads to hepatic insulin resistance and steatosis. Additionally, it secretes a profile of pro-inflammatory adipokines (e.g., TNF-α, IL-6) and reduced amounts of the insulin-sensitizing adipokine, adiponectin. These factors contribute to a state of chronic low-grade inflammation and promote systemic insulin resistance.
* A is incorrect because adipose tissue does not secrete insulin; that is the function of pancreatic beta-cells.
* C is incorrect because T2DM is not a state of chronic ketosis, and this is not a recognized mechanism of beta-cell damage.
* D is incorrect because SGLT1 transporters are primarily in the intestine and kidney, not adipose tissue, and their function is related to glucose absorption/reabsorption, not competition that would cause hypoglycemia.
- A physician is evaluating four patients for diabetes. The results of their fasting blood tests are shown in the table. Which patient's profile is most consistent with the pathophysiology of established Type 1 diabetes? Use the table to answer the question.
Answer: Patient C
Established Type 1 diabetes is defined by autoimmune destruction of beta-cells, leading to absolute insulin deficiency. The expected lab profile is therefore: 1) hyperglycemia, 2) very low or undetectable insulin, 3) very low or undetectable C-peptide (a marker of endogenous insulin production), and 4) the presence of autoantibodies (like GAD65 Ab). Patient C's profile perfectly matches these criteria.
* A is incorrect: Patient A has hyperglycemia with high insulin and C-peptide, classic for Type 2 diabetes with severe insulin resistance.
* B is incorrect: Patient B has normal glucose, insulin, and C-peptide, representing a healthy state.
* D is incorrect: Patient D has hyperglycemia with normal-to-high insulin and C-peptide, suggestive of early Type 2 diabetes or pre-diabetes with insulin resistance.
